Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Johan Bodegard
Are there lost opportunities in chronic kidney disease? A region-wide cohort study
Are there lost opportunities in chronic kidney disease? A region-wide cohort study Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort
Introduction The global prevalence of heart failure is expected to increase beyond the 64 million people that it currently affects.1 Subsequently, its burden to healthcare systems is also expected to increase, exceeding the proportion (1–2%) of the annual healthcare budget that is currently allocated towards the condition.2, 3 The characteristics and prognosis of patients with heart failure change over time with the development of new treatments and updated guidelines.4-12 Therefore, there is...
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF
Introduction Heart failure (HF) is common, and its prevalence is expected to rise with aging populations and improved diagnosis.1,2 HF is associated with an impaired quality of life, poor outcomes, and places a substantial economic burden on health care systems.3 Treatment strategies to improve prognosis vary depending on left ventricular ejection fraction (LVEF). For patients with heart failure with preserved ejection fraction (HFpEF), guideline-recommended treatments are currently limited.
History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case-control study | BMJ Open
Discussion In this nationwide study including all patients with CRD hospitalised for COVID-19 during all three waves in Sweden, there are several important findings. First, hospitalisation for COVID-19 was associated with a 50% increased risk for mortality both in the CRD and the reference group compared with being hospitalised for influenza in the previous years illustrating that COVID-19 during the first waves was a more severe disease than influenza.
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
Hospital healthcare costs in a population with heart failure The cumulative costs analyses account for repeated events, rather than the time to first event. This provided the capacity to demonstrate that, over a 5 year period, hospital healthcare costs in patients with heart failure were mainly driven by cardiorenal events, and to a lesser extent by atherosclerotic cardiovascular disease events, further highlighting the need for improved cardiorenal prevention and management.
Heart Failure Drug Titration, Discontinuation, Mortality and Heart Failure Hospitalization Risk: A Multinational Observational Study (US, UK and Sweden)
Research Article Gianluigi Savarese MD PhD, Corresponding Author gianluigi.savarese@ki.se Division of Cardiology, Department of Medicine, Karolinska Institute, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden Corresponding author.
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
Cardiovascular and Metabolic Risk Abstract OBJECTIVE Type 1 diabetes (T1D) and type 2 diabetes (T2D) increase risks of cardiovascular (CV) and renal disease (CVRD) compared with diabetes-free populations. Direct comparisons between T1D and T2D are scarce. We examined this by pooling full-population cohorts in Sweden and Norway.
Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
Abstract Aims To examine heart failure (HF) and chronic kidney disease (CKD) risks reduction associated with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) compared to other glucose‐lowering drugs (oGLD) in the early stage of type 2 diabetes patients without established cardiovascular or renal diseases (CVRD‐free T2D). Materials and Methods We performed an observational cohort study using a Japanese hospital claims registry, Medical Data Vision.
Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
Abstract Aims We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular and renal disease, defined as cardiovascular and renal disease (CVRD) free, managed in routine clinical practice.
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Abstract Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date.
Dapagliflozin vs Non‐SGLT‐2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE‐TIMI 58 Participants: A Nationwide Observational Study - Norhammar - - Diabetes, Obesity and Metabolism - Wiley Online
ORIGINAL ARTICLE Dapagliflozin vs Non‐SGLT‐2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE‐TIMI 58 Participants: A Nationwide Observational Study Johan Bodegard MD PhD Corresponding Author E-mail address: johan.bodegard@astrazeneca.com https://orcid.org/0000-0001-5423-3967 AstraZeneca Nordic‐Baltic, Oslo, Norway Correspondence Dr. Johan Bodegård, AstraZeneca, Nordic‐Baltic, Oslo, Norway , Mail: Email: johan.bodegard@astrazeneca.com,...
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study - Norhammar - - Diabetes, Obesity and Metabolism - Wiley Online Library
Abstract Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the main inclusion criteria and outcomes from the DECLARE‐TIMI 58 study. Methods Patients with new initiation of dapagliflozin and/or other GLDs were identified in Swedish nationwide healthcare registries for the period 2013 to 2016.
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study - Birkeland - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
Abstract Aims Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is), which impacts the relationship between a trial population and the general type 2 diabetes (T2D) population. The aim of this study was to evaluate the representativeness of four SGLT‐2i CVOTs of a general T2D population. Methods T2D patients from Germany, The Netherlands, Norway and Sweden were included in the study.
Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE‐TIMI 58 Participants: A Nationwide Observational Study - Norhammar - - Diabetes, Obesity and Metabolism - Wiley Online Library
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10
We read with interest the Perspective by Suissa (1), in which concerns were raised about our recently published article (2). We thank the author for important points raised and appreciate the concern about the lower rate of all-cause death associated with sodium–glucose cotransporter 2 inhibitors (SGLT2i) compared with insulin treatment in a broad population with type 2 diabetes.
Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients - Nyström - 2017 - Diabetes, Obesity and Metabolism - Wiley Online Libra
To investigate the association of novel oral glucose lowering drugs (GLDs) compared with insulin to risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Johan
Contact Johan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack